Lagoda Investment Management LP Has Boosted Its Alexion Pharmaceuticals (ALXN) Holding, Hill-Rom Holdings, Inc. (HRC) Had 5 Bullish Analysts

May 30, 2017 - By Hazel Jackson

Lagoda Investment Management Lp increased Alexion Pharmaceuticals Inc (ALXN) stake by 2.12% reported in 2016Q4 SEC filing. Lagoda Investment Management Lp acquired 3,349 shares as Alexion Pharmaceuticals Inc (ALXN)’s stock declined 11.63%. The Lagoda Investment Management Lp holds 161,202 shares with $19.72 million value, up from 157,853 last quarter. Alexion Pharmaceuticals Inc now has $21.76 billion valuation. The stock decreased 0.81% or $0.8 during the last trading session, reaching $97.7. About 12 shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since May 30, 2016 and is downtrending. It has underperformed by 34.82% the S&P500.

Among 6 analysts covering Hill-Rom (NYSE:HRC), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Hill-Rom had 7 analyst reports since September 23, 2015 according to SRatingsIntel. Northcoast upgraded the stock to “Buy” rating in Wednesday, December 16 report. Barclays Capital initiated the shares of HRC in report on Wednesday, February 8 with “Overweight” rating. The firm has “Overweight” rating by KeyBanc Capital Markets given on Thursday, January 21. The stock of Hill-Rom Holdings, Inc. (NYSE:HRC) earned “Buy” rating by Stifel Nicolaus on Tuesday, January 24. Stifel Nicolaus maintained Hill-Rom Holdings, Inc. (NYSE:HRC) rating on Monday, May 1. Stifel Nicolaus has “Buy” rating and $84 target. Morgan Stanley upgraded the stock to “Overweight” rating in Thursday, June 16 report. The company was reinitiated on Wednesday, September 23 by Goldman Sachs. See Hill-Rom Holdings, Inc. (NYSE:HRC) latest ratings:

01/05/2017 Broker: Stifel Nicolaus Rating: Buy Old Target: $70.00 New Target: $84.00 Maintain
08/02/2017 Broker: Barclays Capital Rating: Overweight New Target: $70 Initiate
24/01/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $70 Initiate

Since December 9, 2016, it had 0 insider purchases, and 27 sales for $14.61 million activity. Thiel Carsten sold 3,783 shares worth $495,611. 651 shares were sold by O’Neill Julie, worth $87,104. $14,499 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was sold by BELL LEONARD on Tuesday, January 10. $237,516 worth of stock was sold by Moriarty John B on Monday, February 27. 1,932 shares were sold by Wagner Heidi L, worth $243,371 on Monday, February 6. MACKAY MARTIN sold 1,855 shares worth $244,170. Another trade for 3,570 shares valued at $449,135 was made by Carmichael Clare on Monday, February 6.

Among 22 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 17 have Buy rating, 0 Sell and 5 Hold. Therefore 77% are positive. Alexion Pharmaceuticals Inc. had 48 analyst reports since July 27, 2015 according to SRatingsIntel. The firm has “Overweight” rating by Morgan Stanley given on Friday, October 2. The company was downgraded on Thursday, January 7 by BTIG Research. The stock has “Buy” rating by UBS on Thursday, February 4. Stifel Nicolaus maintained it with “Buy” rating and $245 target in Friday, December 11 report. The company was initiated on Wednesday, July 13 by RBC Capital Markets. The firm earned “Buy” rating on Friday, October 28 by Goldman Sachs. The rating was initiated by Wedbush with “Neutral” on Friday, September 23. The firm earned “Outperform” rating on Monday, July 11 by Credit Suisse. The stock has “Overweight” rating by Barclays Capital on Tuesday, November 29. The firm has “Mkt Perform” rating given on Friday, October 28 by FBR Capital.

Lagoda Investment Management Lp decreased T2 Biosystems Inc (NASDAQ:TTOO) stake by 148,851 shares to 1.73M valued at $9.12M in 2016Q4. It also reduced Ptc Inc (NASDAQ:PTC) stake by 11,013 shares and now owns 497,750 shares. Renaissancere Holdings Ltd (NYSE:RNR) was reduced too.

Investors sentiment is 1.07 in 2016 Q4. Its the same as in 2016Q3. It is the same, as 59 investors sold ALXN shares while 167 reduced holdings. only 81 funds opened positions while 160 raised stakes. 215.83 million shares or 2.26% more from 211.05 million shares in 2016Q3 were reported. 12,196 were accumulated by Old Bankshares In. First Personal Financial Service owns 0.01% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 154 shares. Korea Corp owns 0.2% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 340,585 shares. 2,045 are held by Glenmede Trust Na. Gemmer Asset Ltd Limited Liability Company invested 0.01% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Sg Americas Ltd Llc reported 59,315 shares. Dubuque Retail Bank And Trust Comm has invested 0% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Hanson Mcclain has invested 0% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Wall Street Associate holds 2,000 shares. 182 are held by Hudock Capital Group Ltd. Tekla Cap Mngmt Ltd stated it has 4.15% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). United Capital Financial Advisers Limited Liability Corp accumulated 2,284 shares. First Tru Advisors LP holds 269,222 shares. 11,000 were accumulated by Leavell Inv Management. Cam Group Inc A S owns 38,664 shares for 0.09% of their portfolio.

Investors sentiment increased to 1.42 in Q4 2016. Its up 0.04, from 1.38 in 2016Q3. It increased, as 34 investors sold Hill-Rom Holdings, Inc. shares while 72 reduced holdings. 45 funds opened positions while 105 raised stakes. 54.15 million shares or 0.55% more from 53.85 million shares in 2016Q3 were reported. 43,616 are owned by Texas Permanent School Fund. Us State Bank De holds 0% of its portfolio in Hill-Rom Holdings, Inc. (NYSE:HRC) for 4,612 shares. Trexquant L P stated it has 0.12% in Hill-Rom Holdings, Inc. (NYSE:HRC). Axa has invested 0.04% in Hill-Rom Holdings, Inc. (NYSE:HRC). Fdx Advsrs has invested 0.01% in Hill-Rom Holdings, Inc. (NYSE:HRC). Retirement System Of Alabama, a Alabama-based fund reported 111,225 shares. First Quadrant Limited Partnership Ca owns 12,300 shares. Qs Investors Limited Liability Com holds 0% of its portfolio in Hill-Rom Holdings, Inc. (NYSE:HRC) for 131 shares. Jacobs Levy Equity Mgmt has invested 0.06% of its portfolio in Hill-Rom Holdings, Inc. (NYSE:HRC). Geneva Advsr reported 3,853 shares stake. Suntrust Banks holds 0.02% or 70,146 shares in its portfolio. Ls Inv Advsrs Ltd Liability holds 4,321 shares. New York State Common Retirement Fund has invested 0.01% in Hill-Rom Holdings, Inc. (NYSE:HRC). Royal Bancorp Of Canada holds 0% or 6,033 shares in its portfolio. Glenmede Tru Com Na reported 36,808 shares or 0.01% of all its holdings.

The stock decreased 0.10% or $0.08 on May 26, reaching $76.53. About shares traded. Hill-Rom Holdings, Inc. (NYSE:HRC) has risen 57.47% since May 30, 2016 and is uptrending. It has outperformed by 40.77% the S&P500.

Hill-Rom Holdings, Inc. is a global medical technology company. The company has market cap of $5.03 billion. The Firm operates through four divisions: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. It has a 33.01 P/E ratio. The Company’s services and products include Patient Support Systems, Front Line Care and Surgical Solutions.

Since February 9, 2017, it had 0 buys, and 5 insider sales for $15.12 million activity. Johnson Paul Sherwood sold $85,516 worth of Hill-Rom Holdings, Inc. (NYSE:HRC) on Thursday, February 9. On Friday, March 3 GREISCH JOHN J sold $13.70M worth of Hill-Rom Holdings, Inc. (NYSE:HRC) or 207,987 shares. On Thursday, March 16 the insider SHADER ALTON sold $1.04 million. Richardson Jason had sold 1,947 shares worth $143,124 on Monday, May 15.